KR102558892B1 - 안정화된 비단백질 클로스트리듐 독소 조성물 - Google Patents

안정화된 비단백질 클로스트리듐 독소 조성물 Download PDF

Info

Publication number
KR102558892B1
KR102558892B1 KR1020227031629A KR20227031629A KR102558892B1 KR 102558892 B1 KR102558892 B1 KR 102558892B1 KR 1020227031629 A KR1020227031629 A KR 1020227031629A KR 20227031629 A KR20227031629 A KR 20227031629A KR 102558892 B1 KR102558892 B1 KR 102558892B1
Authority
KR
South Korea
Prior art keywords
composition
clostridial toxin
botulinum toxin
sites
bont
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227031629A
Other languages
English (en)
Korean (ko)
Other versions
KR20220132013A (ko
Inventor
모리스 아비아드
바스 다니
에브게니 샬라에브
Original Assignee
알레간 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59974865&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102558892(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 알레간 인코포레이티드 filed Critical 알레간 인코포레이티드
Publication of KR20220132013A publication Critical patent/KR20220132013A/ko
Application granted granted Critical
Publication of KR102558892B1 publication Critical patent/KR102558892B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
KR1020227031629A 2016-09-13 2017-09-13 안정화된 비단백질 클로스트리듐 독소 조성물 Active KR102558892B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662394009P 2016-09-13 2016-09-13
US62/394,009 2016-09-13
KR1020197010226A KR102444230B1 (ko) 2016-09-13 2017-09-13 안정화된 비단백질 클로스트리듐 독소 조성물
PCT/US2017/051394 WO2018053021A1 (en) 2016-09-13 2017-09-13 Stabilized non-protein clostridial toxin compositions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197010226A Division KR102444230B1 (ko) 2016-09-13 2017-09-13 안정화된 비단백질 클로스트리듐 독소 조성물

Publications (2)

Publication Number Publication Date
KR20220132013A KR20220132013A (ko) 2022-09-29
KR102558892B1 true KR102558892B1 (ko) 2023-07-21

Family

ID=59974865

Family Applications (6)

Application Number Title Priority Date Filing Date
KR1020197010226A Active KR102444230B1 (ko) 2016-09-13 2017-09-13 안정화된 비단백질 클로스트리듐 독소 조성물
KR1020257007508A Pending KR20250038828A (ko) 2016-09-13 2017-09-13 안정화된 비단백질 클로스트리듐 독소 조성물
KR1020197010225A Active KR102480965B1 (ko) 2016-09-13 2017-09-13 안정화된 비단백질 클로스트리듐 독소 조성물
KR1020227044818A Active KR102635959B1 (ko) 2016-09-13 2017-09-13 안정화된 비단백질 클로스트리듐 독소 조성물
KR1020247004403A Ceased KR20240023684A (ko) 2016-09-13 2017-09-13 안정화된 비단백질 클로스트리듐 독소 조성물
KR1020227031629A Active KR102558892B1 (ko) 2016-09-13 2017-09-13 안정화된 비단백질 클로스트리듐 독소 조성물

Family Applications Before (5)

Application Number Title Priority Date Filing Date
KR1020197010226A Active KR102444230B1 (ko) 2016-09-13 2017-09-13 안정화된 비단백질 클로스트리듐 독소 조성물
KR1020257007508A Pending KR20250038828A (ko) 2016-09-13 2017-09-13 안정화된 비단백질 클로스트리듐 독소 조성물
KR1020197010225A Active KR102480965B1 (ko) 2016-09-13 2017-09-13 안정화된 비단백질 클로스트리듐 독소 조성물
KR1020227044818A Active KR102635959B1 (ko) 2016-09-13 2017-09-13 안정화된 비단백질 클로스트리듐 독소 조성물
KR1020247004403A Ceased KR20240023684A (ko) 2016-09-13 2017-09-13 안정화된 비단백질 클로스트리듐 독소 조성물

Country Status (28)

Country Link
US (10) US10369190B2 (enExample)
EP (4) EP3432916B1 (enExample)
JP (4) JP2019526611A (enExample)
KR (6) KR102444230B1 (enExample)
CN (3) CN109803672A (enExample)
AU (4) AU2017326253B2 (enExample)
BR (2) BR112019004929A2 (enExample)
CA (2) CA3035473A1 (enExample)
CL (1) CL2019000586A1 (enExample)
CO (1) CO2019003630A2 (enExample)
CY (2) CY1122263T1 (enExample)
DK (2) DK3436054T4 (enExample)
ES (2) ES2755815T3 (enExample)
HR (1) HRP20191966T4 (enExample)
HU (2) HUE046449T2 (enExample)
IL (2) IL265109B2 (enExample)
LT (1) LT3436054T (enExample)
MX (2) MX2019002835A (enExample)
PH (1) PH12019500501A1 (enExample)
PL (2) PL3432916T3 (enExample)
PT (2) PT3436054T (enExample)
RS (1) RS59600B2 (enExample)
RU (2) RU2762607C2 (enExample)
SA (1) SA519401298B1 (enExample)
SI (2) SI3432916T1 (enExample)
SM (1) SMT201900625T1 (enExample)
TW (2) TWI773686B (enExample)
WO (2) WO2018053021A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
RU2762607C2 (ru) 2016-09-13 2021-12-21 Аллерган, Инк. Стабилизированные небелковые композиции клостридиального токсина
KR102649069B1 (ko) 2018-05-31 2024-03-19 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 안면 홍조 개선용 조성물
WO2020027466A1 (ko) 2018-07-28 2020-02-06 주식회사 엑소코바이오 엑소좀의 동결건조 방법
KR102163806B1 (ko) 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
CA3112394A1 (en) * 2018-09-13 2020-03-19 Allergan, Inc. Clostridial toxin - hyaluronic acid compositions
KR102259423B1 (ko) * 2018-11-30 2021-06-02 주식회사 휴온스바이오파마 보툴리눔 독소의 안정화 액상 조성물
WO2020231700A1 (en) * 2019-05-11 2020-11-19 Youngsuk Yi Neurotoxin compositions and methods
AR119101A1 (es) * 2019-06-07 2021-11-24 Nestle Skin Health S A Tratamiento de líneas glabelares y líneas cantales laterales de moderadas a muy graves
US11090371B1 (en) 2019-10-18 2021-08-17 Penland Foundation Treatment of cirrhosis using botulinum toxin
US11738071B2 (en) 2021-07-12 2023-08-29 Penland Foundation Treatment of acute and chronic kidney disease
US10987411B1 (en) 2019-10-18 2021-04-27 Penland Foundation Treatment of chronic obstructive pulmonary disease using botulinum toxin
CA3227431A1 (en) 2019-10-18 2021-04-22 Penland Foundation Use of a botulinum toxin for treating autism and/or tolerance to narcotics
US10960060B1 (en) * 2019-10-18 2021-03-30 Penland Foundation Treatment of cardiac arrhythmia using botulinum toxin
US11241479B2 (en) 2019-10-18 2022-02-08 Penland Foundation Treatment methods using botulinum toxins
US10973873B1 (en) 2019-10-18 2021-04-13 Penland Foundation Treatment of asthma using botulinum toxin
US10967052B1 (en) 2019-10-18 2021-04-06 Penland Foundation Treatment of dyslexia using botulinum toxin
US10960061B1 (en) 2019-10-18 2021-03-30 Penland Foundation Treatment of amyotrophic lateral sclerosis using botulinum toxin
WO2021231669A1 (en) * 2020-05-15 2021-11-18 Penland Foundation Treatment of cardiac arrhythmia using botulinum toxin
RU2746035C1 (ru) * 2020-06-30 2021-04-06 Государственное бюджетное учреждение Санкт-Петербургский научно-исследовательский институт скорой помощи им. И.И. Джанелидзе Способ купирования болевого синдрома после эндопротезирования молочных желез
WO2023287728A1 (en) 2021-07-12 2023-01-19 Penland Foundation Treatment of diabetes and chronic pancreatitis using botulinum toxin
WO2024102345A1 (en) 2022-11-07 2024-05-16 Allergan, Inc. Prevention of post-operative atrial fibrillation with a botulinum toxin
GB202318884D0 (en) * 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation
CN118697853B (zh) * 2024-06-27 2025-05-02 河北封章生物科技有限公司 一种稳定性提高的肉毒素制剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140120077A1 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and Methods for Safe Treatment of Rhinitis

Family Cites Families (448)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0229810B1 (en) 1985-07-09 1991-10-16 Quadrant Bioresources Limited Protection of proteins and the like
US4958257A (en) 1989-03-29 1990-09-18 Hughes Aircraft Company Heat conducting interface for electronic module
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
IL101007A (en) 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
WO1993017700A1 (en) * 1992-03-13 1993-09-16 Beardsley Terry R Immune-enhancing agent for therapeutic use in immunocompromised hosts
JP3510886B2 (ja) 1992-06-23 2004-03-29 ボツリヌム トキシン リサーチ アソシエイト インコーポレイテッド ボツリヌスｂ複合体を含有する医薬組成物
EP1790352B1 (en) * 1993-12-28 2008-07-09 Allergan, Inc. Use of botulinum toxin for the manufacture of a medicament for reducing low back pain
PT1086702E (pt) 1994-05-09 2005-08-31 William J Binder Neurotoxinas pre-sinapticas para tratamento da dor de cabeca devida a enxaqueca
US6203794B1 (en) 1994-05-31 2001-03-20 Allergan Sales, Inc. Modification of clostridial toxins for use as transport proteins
US5962637A (en) 1994-06-03 1999-10-05 Microbiological Research Authority Toxin assay
GB9411138D0 (en) 1994-06-03 1994-07-27 Microbiological Res Authority Toxin assay
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US5756468A (en) 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5556771A (en) 1995-02-10 1996-09-17 Gen-Probe Incorporated Stabilized compositions of reverse transcriptase and RNA polymerase for nucleic acid amplification
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
AU4746096A (en) 1995-06-06 1996-12-24 Wisconsin Alumni Research Foundation Analogs of botulinum toxin and pharmaceutical compositions o f botulinum toxin
WO1996039167A1 (en) 1995-06-06 1996-12-12 Pearce L Bruce Improved compositions and methods for chemodenervation using neurotoxins
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US8828432B2 (en) 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
TW518235B (en) 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
US6777196B2 (en) 1997-02-18 2004-08-17 Genentech, Inc. Neurturin receptor
US9066943B2 (en) 1997-07-15 2015-06-30 The Regents Of The University Of Colorado Use of botulinum toxin therapy for treatment of urological neurological conditions
EP1475099B2 (en) 1997-07-15 2014-04-09 The Regents of the University of Colorado Use of botulinum toxin to treat urinary incontinence
US6638621B2 (en) 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
CN1073626C (zh) 1997-10-18 2001-10-24 卫生部兰州生物制品研究所 A型肉毒结晶毒素的生产工艺及生产该毒素所需的冻干保护液
SE510813C2 (sv) 1997-12-08 1999-06-28 Arla Ekonomisk Foerening Bakteriestam av arten Lactobacillus Paracasei subsp. paracasei, sammansättning därav för användning i livsmedel, samt produkt innehållande stammen
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US20050147690A1 (en) 1998-09-25 2005-07-07 Masters David B. Biocompatible protein particles, particle devices and methods thereof
PT1031346E (pt) 1999-01-27 2002-09-30 Idea Ag Vacinacao nao invasiva atraves da pele
EP1031347B1 (en) 1999-01-27 2002-04-17 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
US6573244B1 (en) 1999-05-17 2003-06-03 The United States Of America As Represented By The Secretary Of The Army Previns as specific inhibitors and therapeutic agents for Botulinum toxin B and Tetanus neurotoxins
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6977080B1 (en) 1999-08-10 2005-12-20 Allergan, Inc. Intrapericardial botulinum toxin treatment for bradycardia
AU777556B2 (en) 1999-08-25 2004-10-21 Allergan, Inc. Activatable recombinant neurotoxins
US20030180289A1 (en) 1999-09-23 2003-09-25 Foster Keith Alan Inhibition of secretion from non-neuronal cells
PT1221968E (pt) 1999-10-13 2010-04-16 Novartis Vaccines & Diagnostic Processo de obtenção de respostas imunes celulares de proteínas
IL149778A0 (en) 1999-11-22 2002-11-10 Universal Preservation Technologies Inc Preservation of sensitive biological material
US6500436B2 (en) 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20030138460A1 (en) 2000-02-08 2003-07-24 Allergan, Inc Methods of treating animals with botulinum toxin pharmaceutical compositions
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
EP1514556B1 (en) 2000-02-08 2011-08-10 Allergan, Inc. Botulinum toxin pharmaceutical compositions
US8632785B2 (en) 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US20060269575A1 (en) 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US20040033241A1 (en) 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US7491799B2 (en) 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US6653062B1 (en) 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
US6630330B1 (en) 2000-08-02 2003-10-07 Biopolo S.C.A.R.L. Ascorbic acid production from yeast
EA006759B1 (ru) 2000-10-31 2006-04-28 Бёрингер Ингельхайм Фармасьютиклз, Инк. Пероральные лекарственные самоэмульгирующиеся композиции ингибиторов протеазы из класса пиранонов
US7223577B2 (en) 2000-11-17 2007-05-29 Allergan, Inc. Post-translational modifications and Clostridial neurotoxins
US7273722B2 (en) 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
ITUD20010002A1 (it) 2001-01-05 2002-07-05 Univ Degli Studi Udine Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo
US7442686B2 (en) 2001-04-12 2008-10-28 Bioaxone Therapeutique Inc. Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
US20060134140A1 (en) 2001-04-12 2006-06-22 Dana Lasko Compositions and methods for treating tumor spreading
EP1390053A2 (en) 2001-04-25 2004-02-25 Hernan F. Acevedo Hcg formulation
US9157875B2 (en) 2001-05-16 2015-10-13 Benjamin P. Warner Drug development and manufacturing
US8022172B2 (en) 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
US7332567B2 (en) 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US7208285B2 (en) 2001-08-28 2007-04-24 Allergan, Inc. Fret protease assays for botulinum serotype A/E toxins
US20030104996A1 (en) 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
MXPA01011542A (es) 2001-11-13 2003-05-22 Alcon Inc Regeneracion del cartilago articular da°ado por la osteoartritis de grado i y ii, mediante la aplicacion intra-articular de una mezcla de hialuronato de sodio y de condroitin sulfato en un vehiculo de gel.
US7491403B2 (en) 2002-12-20 2009-02-17 Botulinum Toxin Research Associates Pharmaceutical botulinum toxin compositions
US7691394B2 (en) 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US7183066B2 (en) 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
BR0314558A (pt) 2002-10-10 2005-08-09 Diversa Corp Proteases, ácidos nucléicos codificando as mesmas e processos para preparar e usar as mesmas
US20060140984A1 (en) 2002-10-25 2006-06-29 Foamix Ltd. Cosmetic and pharmaceutical foam
US20040086532A1 (en) 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
US20040143213A1 (en) 2002-11-12 2004-07-22 Collegium Pharmaceutical, Inc. Inertial drug delivery system
US20060074014A1 (en) 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20060002862A1 (en) 2002-12-17 2006-01-05 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
GB0300427D0 (en) 2003-01-09 2003-02-05 Univ Strathclyde Pharmaceutical composition
ATE407117T1 (de) 2003-01-16 2008-09-15 Acadia Pharm Inc Selektive serotonin 2a/2c inverse rezeptoragonisten als therapeutika für neurodegenerative erkrankungen
US7758872B1 (en) 2003-02-07 2010-07-20 Eric Finzi Method of treating depression
US20060153876A1 (en) 2003-02-24 2006-07-13 Ira Sanders Cell membrane translocation of regulated snare inhibitors, compositions therefor, and methods for treatment of disease
WO2004078140A2 (en) 2003-03-05 2004-09-16 Halozyme, Inc. SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20040214753A1 (en) 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
US20040204471A1 (en) 2003-03-20 2004-10-14 Pharmacia Corporation Treatment and prevention of otic disorders with Cox-2 inhibitors alone or in combination with otic agents
US9006388B2 (en) 2003-03-26 2015-04-14 Sudhir Paul Covalent attachment of ligands to nucleophilic proteins guided by non-covalent
US7341843B2 (en) 2003-04-11 2008-03-11 Allergan, Inc. Botulinum toxin A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
US7396535B2 (en) 2003-04-25 2008-07-08 Ackerman Alan H Therapy for obsessive compulsive head banging
US7393537B2 (en) 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
JP2007521092A (ja) 2003-07-02 2007-08-02 アルザ・コーポレーシヨン 小突起アレイの免疫化パッチおよび方法
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US20050042775A1 (en) 2003-08-21 2005-02-24 Nicholas Pomato Botulinum antitoxin compositions and methods
EP1660013A4 (en) 2003-08-26 2011-07-20 Gel Del Technologies Inc BIOMATERIAL AND PROTEIN BIOCOACERVATES, METHODS OF MAKING AND USING THEM
US7148041B2 (en) 2003-09-25 2006-12-12 Allergan, Inc. Animal product free media and processes for obtaining a botulinum toxin
US7160699B2 (en) 2003-09-25 2007-01-09 Allergan, Inc. Media for clostridium bacterium and processes for obtaining a clostridial toxin
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
EP1680178A4 (en) 2003-10-31 2008-01-02 Alza Corp SYSTEM AND METHOD FOR THE TRANSDERMAL DISTRIBUTION OF A VACCINE
KR20070011252A (ko) 2003-11-21 2007-01-24 알자 코포레이션 초음파 보조 경피 백신전달방법 및 시스템
GB0328060D0 (en) 2003-12-04 2004-01-07 Sod Conseils Rech Applic Botulinum toxin treatment
WO2005055945A2 (en) 2003-12-08 2005-06-23 Gel-Del Technologies, Inc. Mucoadhesive drug delivery devices and methods of making and using thereof
EP2492261B1 (en) 2003-12-23 2015-02-18 Infinity Discovery, Inc. Analogs of benzoquinone-containing ansamycins for the treatment of cancer
CA2552754A1 (en) 2004-01-09 2005-08-04 Alza Corporation Frequency assisted transdermal agent delivery method and system
FR2865131B1 (fr) 2004-01-15 2007-08-24 Gattefosse Ets Sa Utilisation d'un extrait d'acmella oleracea pour son effet botox like dans une composition cosmetique anti-rides
JP4970057B2 (ja) 2004-02-24 2012-07-04 アラーガン、インコーポレイテッド ボツリヌス毒素スクリーニングアッセイ
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US9078892B2 (en) 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US20050191321A1 (en) 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
ES2691498T3 (es) 2004-03-03 2018-11-27 Revance Therapeutics, Inc. Aplicación tópica y liberación transdérmica de toxinas botulínicas
US7674454B2 (en) 2004-03-06 2010-03-09 Innovata Limited Enzyme-prodrug therapy for prosthetic joint repair
US20050214325A1 (en) 2004-03-26 2005-09-29 Vvii Newco 2003, Inc. Compositions and methods to increase the effect of a neurotoxin treatment
MXPA06011429A (es) 2004-04-01 2007-04-25 Johnson & Johnson Aparato y metodo para el suministro transdermico de la vacuna contra la influenza.
NZ550150A (en) 2004-04-09 2009-05-31 Wyeth Corp Synergistic attenuation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof
JP2007537783A (ja) 2004-04-13 2007-12-27 アルザ コーポレイション 複数のワクチンを経皮送達するための装置及び方法
ATE380880T1 (de) 2004-05-05 2007-12-15 Pharmaleads Mittels botulinumtoxin a (bont/a) erkennbare peptidsubstrate und verwendung
US7591806B2 (en) 2004-05-18 2009-09-22 Bai Xu High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances
EP1747672A4 (en) 2004-05-19 2010-02-17 Alza Corp METHOD AND FORMULATION OF TRANSDERMAL DELIVERY OF IMMUNOLOGICALLY ACTIVE AGENTS
DE102004026152A1 (de) 2004-05-28 2005-12-15 Basf Ag Fermentative Herstellung von Feinchemikalien
JP2008502605A (ja) 2004-06-16 2008-01-31 スマート ドラッグ システムズ インコーポレイティド 徐放性ワクチン組成物
WO2006000229A2 (en) 2004-06-28 2006-01-05 Lifecycle Pharma A/S Porous tablets as carriers for liquid formulations
WO2006011966A1 (en) 2004-06-30 2006-02-02 Allergan, Inc. Optimizing expression of active botulinum toxin type e
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
CA2578250C (en) 2004-07-26 2013-03-05 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition with a botulinum neurotoxin
PL1776137T3 (pl) 2004-08-04 2015-03-31 Ipsen Biopharm Ltd Kompozycja farmaceutyczna zawierająca neurotoksynę botulinową
GB2419527A (en) 2004-10-28 2006-05-03 Ipsen Ltd Pharmaceutical composition containing botulinum neurotoxin
AU2005271372B2 (en) 2004-08-04 2012-05-03 Allergan, Inc. Optimizing expression of active botulinum toxin type A
EP1982997B1 (en) 2004-09-01 2012-08-08 Allergan, Inc. Degradable clostridial toxins
WO2006029411A2 (en) 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
CA2518650A1 (en) 2004-09-10 2006-03-10 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
US7399607B2 (en) 2004-09-22 2008-07-15 Allergan, Inc. Fluorescence polarization assays for determining clostridial toxin activity
CN101060831B (zh) 2004-10-01 2010-06-23 拉姆斯科股份有限公司 可方便植入的缓释药物组合物
US20070258992A1 (en) 2004-10-06 2007-11-08 Atassi M Zouhair Determining and Reducing Immunoresistance to Botulinum Toxin Therapy Using Botulinum Toxin a Peptides
US7205018B2 (en) 2004-10-07 2007-04-17 Next Proteins, Inc. Carbonated protein drink and method of making
AU2005301046B2 (en) 2004-11-02 2012-02-23 Chr. Hansen A/S Stabilized bacteriophage formulations
CA2598204C (en) 2004-11-09 2015-01-13 Board Of Regents, The University Of Texas System Stabilized hme composition with small drug particles
CA2595115C (en) 2004-12-01 2014-01-21 Health Protection Agency Fusion proteins for treating, preventing or ameliorating pain
CA2588292C (en) 2004-12-01 2019-01-15 Health Protection Agency Non-cytotoxic protein conjugates
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
WO2006073410A1 (en) 2005-01-03 2006-07-13 Botulinum Toxin Research Associates, Inc. Compositions, methods and devices for preparing less painful botulinum toxin formulations
US20080220021A1 (en) 2005-02-14 2008-09-11 Pankaj Modi Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis
US7838011B2 (en) 2005-02-14 2010-11-23 Pankaj Modi Stabilized protein compositions for topical administration and methods of making same
US7727537B2 (en) 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
EP1861112A4 (en) 2005-03-03 2009-07-22 Revance Therapeutics Inc COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF BOTULINUM TOXINES
KR20070116710A (ko) 2005-03-03 2007-12-11 알러간, 인코포레이티드 보툴리눔 독소를 정제하기 위한 동물 산물이 없는 시스템및 프로세스
JP2008535486A (ja) 2005-03-15 2008-09-04 アラーガン、インコーポレイテッド クロストリジウム毒素標的細胞に対する改変された標的能力を有する修飾クロストリジウム毒素
WO2006106823A1 (ja) 2005-03-31 2006-10-12 Japan Science And Technology Agency 分子マーカーを用いた間葉系幹細胞の識別方法及びその利用
US8124357B2 (en) 2005-04-05 2012-02-28 Allergan, Inc. Lipophilic dye-based fret assays for clostridal toxin activity
US20070029252A1 (en) 2005-04-12 2007-02-08 Dunson James B Jr System and process for biomass treatment
WO2006122123A2 (en) 2005-05-09 2006-11-16 Levin Bruce H Methods of alleviating disorders and their associated pain
US8926991B2 (en) 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
EP2201961B1 (en) 2005-06-27 2018-01-24 GlaxoSmithKline Biologicals S.A. Immunogenic composition
US8323666B2 (en) 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US20070036831A1 (en) 2005-08-09 2007-02-15 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
PT1954308E (pt) 2005-09-16 2011-11-03 Merial Ltd Estabilizadores para vacinas liofilizadas
JP5134540B2 (ja) 2005-09-19 2013-01-30 アラーガン、インコーポレイテッド クロストリジウム毒素活性化クロストリジウム毒素
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
AU2013202329B2 (en) * 2005-10-06 2016-04-14 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
CN101175478A (zh) * 2005-10-06 2008-05-07 阿勒根公司 非蛋白稳定的梭菌毒素药物组合物
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US20090324647A1 (en) 2005-10-11 2009-12-31 Borodic Gary E Albumin-Free Botulinum Toxin Based Pharmaceutical Compositions Containing a Hyaluronidase and Methods of Use
DE102005051789B4 (de) 2005-10-28 2014-08-07 Toxogen Gmbh Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
EP1960547A2 (en) 2005-12-08 2008-08-27 Novartis AG Effects of inhibitors of fgfr3 on gene transcription
US20090035354A1 (en) 2005-12-30 2009-02-05 Mor Research Applications Ltd. Device and Method for Treating the Anal Sphincter
JP2009526755A (ja) 2006-01-10 2009-07-23 ユー， リュイ ジェイ． Ｎ−（ホスホノアルキル）−アミノ酸、その誘導体及び組成物及びその利用法
KR102109867B1 (ko) 2006-01-24 2020-05-13 안선 바이오파르마, 아이엔씨. 고분자 미소 구체들의 조제를 위한 기술
US7666912B2 (en) 2006-03-23 2010-02-23 Massachusetts Eye And Ear Infirmary Compositions and methods for reducing body fat
EP2105500A1 (de) 2008-03-26 2009-09-30 Pharmazell GmbH Neue 12alpha-Hydroxysteroiddehydrogenasen, deren Herstellung und deren Verwendung
US7473559B2 (en) 2006-04-05 2009-01-06 Charles Lee Method for measuring the content of a botulinum toxin in a formulation
US7309602B2 (en) 2006-04-13 2007-12-18 Ambrozea, Inc. Compositions and methods for producing fermentation products and residuals
ITTO20060282A1 (it) 2006-04-14 2007-10-15 Univ Degli Studi Torino Mezzo di coltura e composizione farmaceutica per la rigenerazione del tessuto cartilagineo relativo procedimento relativi usi e prodotti
JP2009543556A (ja) 2006-07-11 2009-12-10 アラーガン、インコーポレイテッド 増強した転位置能力および増強したターゲティング活性を有する改変クロストリジウム毒素
CA2658260A1 (en) 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
DE102006035618A1 (de) 2006-07-31 2008-02-07 Curevac Gmbh Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
US20080044390A1 (en) 2006-08-11 2008-02-21 Xiaowei Jin Methods and compositions for the treatment of neurodegenerative disorders
US9061025B2 (en) 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
US8043845B2 (en) 2006-09-20 2011-10-25 American Sterilizer Company Sterilization indicator
EP2511844B1 (en) 2006-10-10 2015-08-12 XRpro Sciences, Inc. X-ray microscope
EP1917971A1 (en) 2006-10-27 2008-05-07 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Substained release formulations comprising very low molecular weight polymers
EP1921149A1 (en) 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
BRPI0719756A2 (pt) 2006-12-01 2014-01-21 Anterios Inc Nanopartículas de entidades anfifílicas
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
DK2829282T3 (en) 2007-03-22 2018-01-02 Univ Colorado Regents Process for preparing an immunologically active adjuvant-linked dried vaccine composition
WO2008133884A2 (en) 2007-04-23 2008-11-06 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
EP1985276A1 (en) 2007-04-26 2008-10-29 Merz Pharma GmbH & Co. KGaA Treatment of movement disorders by a combined use of a chemodenervating agent and automated movement therapy
CA2690773C (en) 2007-07-10 2013-09-17 Medy-Tox, Inc. Pharmaceutical liquid composition of botulinum toxin with improved stability
JP5503543B2 (ja) 2007-09-14 2014-05-28 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物
US8486467B1 (en) 2007-09-20 2013-07-16 Albert G. Prescott Dermal filler and method of using same
MX350501B (es) 2007-10-12 2017-09-07 Massachusetts Inst Technology Nanotecnologia de vacuna.
BRPI0819648A2 (pt) 2007-11-30 2017-05-23 Univ California sistema de co-cultura, e, métodos de cultura de levedura e produção de halogeneto de metila
KR20150080038A (ko) 2007-11-30 2015-07-08 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US9161970B2 (en) 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
US9044477B2 (en) 2007-12-12 2015-06-02 Allergan, Inc. Botulinum toxin formulation
JP2011510059A (ja) 2008-01-25 2011-03-31 ビー アンド ティー エッセ．エッレ．エッレ． 化粧品分野におけるエステル交換オリーブ油の使用
EP3346005A1 (en) 2008-01-31 2018-07-11 CureVac AG Nucleic acids of formula (i) (nuglxmgnnv)a and derivatives thereof as an immunostimulating agent/adjuvant
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
EP4588519A3 (en) 2008-03-14 2025-10-15 Allergan, Inc. Immuno-based botulinum toxin serotype a activity assays
KR101604515B1 (ko) 2008-03-14 2016-03-17 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
EP2271301A4 (en) 2008-03-27 2014-07-02 Agigma Inc METHOD AND COMPOSITIONS FOR THE DELIVERY OF FUNDS
US8617571B2 (en) 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
US9119866B2 (en) 2008-04-08 2015-09-01 Huiru Wang Glycan-based drugs, therapies and biomarkers
KR101100866B1 (ko) 2008-04-14 2012-01-02 한국과학기술원 게놈 수준에서의 부탄올 생산 미생물의 대사 네트워크 모델 및 이를 이용한 부탄올 생성 미생물의 대사특성분석 및 결실 표적 스크리닝 방법
NZ606047A (en) 2008-04-30 2015-03-27 Xyleco Inc Processing biomass
KR20090120222A (ko) 2008-05-19 2009-11-24 (주)메디톡스 식물 유래 성분 함유 배지 및 가요성 폐쇄 용기를 이용하여클로스트리디움 보툴리눔 독소를 생산하는 방법
CA2725329C (en) 2008-05-23 2013-10-01 The Regents Of The University Of Michigan Nanoemulsion vaccines
KR102080429B1 (ko) 2008-06-26 2020-02-21 안테리오스, 인코퍼레이티드 경피 운반
US8697155B2 (en) 2008-07-22 2014-04-15 Mayo Foundation For Medical Education And Research Treatment of obesity and related disorders
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
CN103725717A (zh) 2008-10-17 2014-04-16 焦耳无限科技公司 微生物的乙醇生产
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
WO2010054406A1 (en) 2008-11-10 2010-05-14 Alnylam Pharmaceuticals, Inc. Novel lipids and compositions for the delivery of therapeutics
CA2745657C (en) 2008-12-04 2022-06-21 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
US9498431B2 (en) 2008-12-10 2016-11-22 Jianjian Xu Controlled releasing composition
EP3067049A1 (en) * 2008-12-10 2016-09-14 Allergan, Inc. Clostridial toxin pharmaceutical compositions
EP2358760B1 (en) 2008-12-19 2015-02-18 Momenta Pharmaceuticals, Inc. Characterization of o-linked glycans
LT2379104T (lt) 2008-12-31 2018-04-10 Revance Therapeutics, Inc. Injekcinės botulino toksino vaisto formos
US9744237B2 (en) 2009-01-29 2017-08-29 Kambiz Thomas Moazed Method and system for effecting changes in pigmented tissue
AU2010208046B2 (en) 2009-01-29 2014-10-02 Forsight Vision4, Inc. Posterior segment drug delivery
MX340772B (es) 2009-02-19 2016-07-26 Merz Pharma Gmbh & Co Kgaa Medios y metodos para fabricar neurotoxina altamente pura.
RU2543650C2 (ru) 2009-03-13 2015-03-10 Аллерган, Инк. Иммунологические тесты на активность эндопептидаз с измененной нацеленностью
ES2689703T3 (es) 2009-03-13 2018-11-15 Allergan, Inc. Células útiles para ensayos de actividad de serotipo A de toxina botulínica basados en la respuesta inmunológica
PT2413947T (pt) 2009-04-01 2020-05-28 Revance Therapeutics Inc Métodos e composições para tratar condições de pele associadas à hiper-reatividade vascular
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
US20180027833A1 (en) 2009-04-24 2018-02-01 Nestec S.A. Shelf-stable fermented dairy products and methods of making same
JP2012524549A (ja) 2009-04-24 2012-10-18 ネステク ソシエテ アノニム 貯蔵安定な発酵乳製品及びその製造方法
US9539233B2 (en) 2009-05-04 2017-01-10 Aridis Pharmaceuticals Inc. Gallium formulation for the treatment and prevention of infectious diseases
NZ711583A (en) 2009-05-05 2017-03-31 Arbutus Biopharma Corp Lipid compositions
WO2013170052A1 (en) 2012-05-09 2013-11-14 Sio2 Medical Products, Inc. Saccharide protective coating for pharmaceutical package
KR102066189B1 (ko) 2009-06-10 2020-01-14 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
WO2010146591A2 (en) 2009-06-18 2010-12-23 Rdd Pharma Ltd. Methods and devices for delivery of pharmaceutical agents within orifices of the body
ES2615281T3 (es) 2009-06-24 2017-06-06 Charles N.S. Soparkar Suplementación con cinc para aumentar la capacidad de respuesta al tratamiento con metaloproteasa
BRPI1015938A2 (pt) * 2009-06-25 2016-09-27 Revance Therapeutics Inc formulações da toxina botulínica livre de albumina
US20120107431A1 (en) 2009-06-30 2012-05-03 Dong Hyun Kim Cosmetic composition containing a rubus coreanus extract for diminishing skin wrinkles
US9458536B2 (en) 2009-07-02 2016-10-04 Sio2 Medical Products, Inc. PECVD coating methods for capped syringes, cartridges and other articles
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
WO2011011796A2 (en) 2009-07-24 2011-01-27 The Regents Of The University Of California Methods and compositions for improving sugar transport, mixed sugar fermentation, and production of biofuels
CN102573802A (zh) 2009-08-12 2012-07-11 希格默伊德药业有限公司 包含聚合物基质和油相的免疫调节组合物
US8821879B2 (en) 2009-09-04 2014-09-02 Xoma Technology Ltd. Anti-botulism antibody coformulations
US20110059079A1 (en) 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody Coformulations
CN106893744A (zh) 2009-09-14 2017-06-27 Gs加特克斯公司 生物燃料物质及生物化学物质的制备方法
EP2513321A2 (en) 2009-12-15 2012-10-24 Stratley AG Method for recovery of organic components from dilute aqueous solutions
WO2011075623A1 (en) 2009-12-18 2011-06-23 Latitude Pharmaceuticals, Inc. One - phase gel compos ition compri s ing phos pholi pids
US10471150B2 (en) 2010-01-20 2019-11-12 Urogen Pharma Ltd. Material and method for treating internal cavities
ES2732150T3 (es) 2010-01-20 2019-11-20 Urogen Pharma Ltd Material y método para tratar cavidades internas
WO2011103465A2 (en) 2010-02-20 2011-08-25 Alexey Gennadievich Zdanovsky Botulinum neurotoxin antigenic compositions and methods
GB201004072D0 (en) 2010-03-11 2010-04-28 Turzi Antoine Process, tube and device for the preparation of wound healant composition
US9327105B2 (en) 2010-03-26 2016-05-03 Itrace Biomedical Inc. Active transdermal drug delivery system and the method thereof
US8940308B2 (en) 2010-03-30 2015-01-27 Allergan, Inc. Methods for treating depression
CN106177940A (zh) 2010-05-26 2016-12-07 西莱克塔生物科技公司 含有佐剂的合成纳米载体的剂量选择
BRPI1002601E2 (pt) 2010-06-01 2020-06-30 Embrapa Pesquisa Agropecuaria composição nanoestruturada de uso veterinário para administração de fármacos
KR101209266B1 (ko) 2010-06-30 2012-12-06 한국과학기술연구원 생분해성 및 온도 감응성 폴리포스파젠계 자성 고분자, 그의 제조 방법 및 용도
WO2012015912A1 (en) 2010-07-30 2012-02-02 Medimmune, Llc Method for purifying active polypeptides or immunocojugates
EP2627318B1 (en) 2010-10-12 2017-08-16 Merz Pharma GmbH & Co. KGaA Formulation suitable for stabilizing proteins, which is free of mammalian excipients
US8685381B2 (en) 2010-10-23 2014-04-01 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
SG189513A1 (en) 2010-10-27 2013-05-31 Quantibact As Capture of target dna and rna by probes comprising intercalator molecules
CN103314101B (zh) 2010-11-03 2016-05-18 加利福尼亚大学董事会 通过蛋白质生物质发酵的重组微生物的生物燃料和化学生产
FR2967913A1 (fr) 2010-11-29 2012-06-01 Vetalis Composition galenique adaptee a l'administration a un animal non-humain, utilisations de celle-ci et methodes associees
HRP20171483T1 (hr) 2011-01-07 2017-12-01 Revance Therapeutics, Inc. Topikalni pripravak koji se sastoji od botulinskog toksina i boje
SG10201804552WA (en) 2011-01-24 2018-07-30 Anterios Inc Nanoparticle compositions, formulations thereof, and uses therefor
EP2675474B1 (en) 2011-02-15 2019-01-16 Vaxiion Therapeutics, LLC Therapeutic compositions and methods for antibody and fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells
AU2012220564A1 (en) 2011-02-23 2013-08-29 Ams Research Corporation Drug releasing pelvic treatment system and method
US20120222979A1 (en) 2011-03-04 2012-09-06 Elwha LLC, a limited liability company of the State of Delaware Glassy compositions
KR101978527B1 (ko) * 2011-03-10 2019-09-03 엑스에리스 파머수티클스, 인크. 펩티드 약물의 비경구 주입을 위한 안정한 제형
CN103458887A (zh) 2011-03-31 2013-12-18 雀巢产品技术援助有限公司 用于增加精氨酸水平的营养组合物及其使用方法
DK2692350T4 (da) 2011-03-31 2023-09-04 Medy Tox Inc Lyofiliseret præparat af botulinumtoksin
US9512495B2 (en) 2011-04-07 2016-12-06 Virdia, Inc. Lignocellulose conversion processes and products
SG193928A1 (en) 2011-04-12 2013-11-29 Nestec Sa Nutritional compositions including branched chain fatty acids for improving gut barrier function
RU2013151083A (ru) 2011-04-18 2015-05-27 Нестек С.А. ПИТАТЕЛЬНЫЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ α-ГИДРОКСИИЗОКАПРОНОВУЮ КИСЛОТУ (α-HICA) И ЦИТРУЛЛИН, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
PT2707031T (pt) 2011-05-08 2019-09-05 Legochem Biosciences Inc Conjugados de proteína e agente ativo e processo para a sua preparação
US20130309273A1 (en) 2012-05-17 2013-11-21 Kimberly Hassett Thermostable Vaccine Compositions and Methods of Preparing Same
JP6110845B2 (ja) 2011-05-17 2017-04-05 ザ リージェント オブ ザ ユニバーシティー オブ コロラド、ア ボディー コーポレート 耐熱性ワクチン組成物及びそれを調製する方法
BR112013032396A2 (pt) 2011-06-17 2016-11-22 Halozyme Inc formulações estáveis de aplicações relacionadas à enzima de degradação de ácido hialurônico
US8586020B2 (en) 2011-06-30 2013-11-19 Korea Institute Of Science And Technology Poly(organophosphazene) composition for biomaterials
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US20130053792A1 (en) 2011-08-24 2013-02-28 Ablative Solutions, Inc. Expandable catheter system for vessel wall injection and muscle and nerve fiber ablation
KR20130022923A (ko) 2011-08-26 2013-03-07 삼성전자주식회사 가상 시점 합성 예측을 이용한 부호화/복호화 장치 및 부호화/복호화 방법
WO2013063280A1 (en) 2011-10-25 2013-05-02 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
PE20181541A1 (es) 2011-10-27 2018-09-26 Massachusetts Inst Technology Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
EP2776603B1 (en) 2011-11-11 2019-03-06 SiO2 Medical Products, Inc. PASSIVATION, pH PROTECTIVE OR LUBRICITY COATING FOR PHARMACEUTICAL PACKAGE, COATING PROCESS AND APPARATUS
EP3360428B1 (en) 2011-12-15 2021-08-04 Société des Produits Nestlé S.A. Cohesive thin liquids to promote safe swallowing in dysphagic patients
US20140356340A1 (en) 2011-12-15 2014-12-04 Nestec S.A. Extensional viscosity to promote safe swallowing of food boluses
LT3130347T (lt) 2011-12-30 2019-10-25 Halozyme Inc Ph20 polipeptido variantai, kompozicijos ir jų panaudojimas
EP2634190A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
CN104254612B (zh) 2012-04-26 2018-06-01 安迪苏法国联合股份有限公司 一种2,4-二羟基丁酸的生产方法
ES2996347T3 (en) 2012-06-29 2025-02-12 Cytosorbents Corp Biocompatible sorbent
US20150297800A1 (en) 2012-07-03 2015-10-22 Sio2 Medical Products, Inc. SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS
WO2014008138A2 (en) 2012-07-03 2014-01-09 Sio2 Medical Products, Inc. SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS
JP6514103B2 (ja) 2012-07-06 2019-05-15 ゲンマブ ビー．ブイ． 三重変異を有する二量体タンパク質
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
BR112015001884B1 (pt) 2012-07-31 2020-12-01 Société des Produits Nestlé S.A. composição nutricional para promover a saúde musculoesquelética em pacientes com doença inflamatória intestinal (ibd), seu uso, e formulação farmacêutica, formulação nutricional, formulação de alimentação por tubo, suplemento alimentar, alimento funcional ou produto de bebida
WO2014025663A1 (en) 2012-08-05 2014-02-13 Absci, Llc Inducible coexpression system
WO2015020982A2 (en) 2013-08-04 2015-02-12 Aquavit Pharmaceuticals, Inc. Direct application system and method for the delivery of bioactive compositions and formulations
US10894062B2 (en) 2012-08-10 2021-01-19 Aquavit Pharmaceuticals, Inc. Vitamin supplement compositions for injection
US10980865B2 (en) 2012-08-10 2021-04-20 Aquavit Pharmaceuticals, Inc. Direct application system and method for the delivery of bioactive compositions and formulations
FR2996855B1 (fr) 2012-10-16 2016-11-11 Lesaffre & Cie Souches de levures pour la production de biomasse sur un substrat comprenant un sucre en c5, leurs procedes d'obtention et utilisations de la biomasse produite
GB201219602D0 (en) 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
CA2880897C (en) 2012-11-21 2020-01-14 Syntaxin Limited Methods for the manufacture of proteolytically processed polypeptides
WO2014078911A1 (en) 2012-11-26 2014-05-30 Borody Thomas J Compositions for the restoration of a fecal microbiota and methods for making and using them
US10564150B2 (en) 2012-12-28 2020-02-18 Cellestis Limited Cell mediated immune response assay
CA2897606C (en) 2013-01-11 2021-05-11 Impossible Foods Inc. Methods and compositions for consumables
WO2014124096A1 (en) 2013-02-06 2014-08-14 Perosphere Inc. Stable glucagon formulations
US9650608B2 (en) 2013-02-22 2017-05-16 Medivet America, Llc Activating adipose-derived stem cells for transplantation
US9662450B2 (en) 2013-03-01 2017-05-30 Sio2 Medical Products, Inc. Plasma or CVD pre-treatment for lubricated pharmaceutical package, coating process and apparatus
US9937099B2 (en) 2013-03-11 2018-04-10 Sio2 Medical Products, Inc. Trilayer coated pharmaceutical packaging with low oxygen transmission rate
EP4234753A3 (en) 2013-03-11 2023-11-01 SiO2 Medical Products, Inc. Coated packaging
US10081654B2 (en) 2013-03-13 2018-09-25 President And Fellows Of Harvard College Stapled and stitched polypeptides and uses thereof
EP2968206A4 (en) 2013-03-15 2016-09-21 Nusirt Sciences Inc TREATMENT OF PETS WITH SIRTUIN ACTIVATORS
EP2970389B1 (en) 2013-03-15 2020-08-19 Rhythm Pharmaceuticals, Inc. Pharmaceutical compositions
US9603799B2 (en) 2013-03-15 2017-03-28 Htd Biosystems Inc. Liposomal vaccine adjuvants and methods of making and using same
EP2986140A4 (en) 2013-03-15 2016-10-19 Nusirt Sciences Inc COMPOSITIONS, PROCESSES AND KIT FOR TREATMENT OF PETS
AU2014242565A1 (en) 2013-03-26 2015-10-15 Premier Nutrition Corporation Methods for enhancing muscle protein synthesis following concurrent training
EP2981249A4 (en) 2013-04-02 2016-11-23 Stc Unm MESOPOROUS ALAN NANOPARTICLES AS A UNIVERSAL PLATFORM FOR ADSORPTION, PRESENTATION, AND ADMINISTRATION OF ANTIGENS
US20160073650A1 (en) 2013-04-16 2016-03-17 Nestec S.A. Shelf-stable fermented dairy products and methods of making same
RU2535115C1 (ru) 2013-05-15 2014-12-10 Бости Трейдинг Лтд Фармацевтический состав, содержащий нейротоксин ботулина
WO2014186754A2 (en) 2013-05-16 2014-11-20 Board Of Regents The University Of Texas System Dry solid aluminum adjuvant-containing vaccines and related methods thereof
CN103257233B (zh) 2013-05-31 2015-08-05 南京祥中生物科技有限公司 一种同时可视化检测多种抗生素、非法添加剂及生物毒素的生物芯片及方法
CN105517434B (zh) 2013-07-02 2019-04-09 奥斯特利亚诺瓦新加坡私人有限公司 一种冷冻干燥包囊细胞的方法、冻干的包囊细胞、含有冻干的包囊细胞的组合物及这种细胞和组合物的用途
US11753656B2 (en) 2013-08-15 2023-09-12 Lallemand Hungary Liquidity Management Llc Methods for the improvement of product yield and production in a microorganism through glycerol recycling
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
CN103705913A (zh) * 2013-12-27 2014-04-09 柳州市工人医院 A型肉毒毒素在制备治疗雷诺综合征药物的应用
BR112016015573A2 (pt) 2014-01-02 2017-10-03 Trelys Inc Composições e métodos para produção biológica de aminoácidos em micro-organismos hidrogenotróficos
US10260111B1 (en) 2014-01-20 2019-04-16 Brett Eric Etchebarne Method of detecting sepsis-related microorganisms and detecting antibiotic-resistant sepsis-related microorganisms in a fluid sample
US10071103B2 (en) 2014-01-29 2018-09-11 Vyome Biosciennces Pvt. Ltd. Treatments for resistant acne
CN106132430A (zh) 2014-02-06 2016-11-16 Xeris药物公司 稳定肽制剂及其制备方法
CA2938790A1 (fr) 2014-02-14 2015-08-20 Vesale Pharma Sa Composition comprenant du bifidobacterium animalis ssp. lactis
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
US9389162B2 (en) 2014-04-10 2016-07-12 City University Of Hong Kong Detection of analyte using coffee-ring effect
RS58440B1 (sr) 2014-04-11 2019-04-30 Medimmune Llc Konjugovana jedinjenja koja sadrže cistein-projektovana antitela
CA2945951A1 (en) 2014-04-15 2015-10-22 Industrial Microbes, Inc. Synthetic methanotrophic microorganisms
GB201407525D0 (en) 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
EP3760186A1 (en) * 2014-04-30 2021-01-06 Allergan, Inc. Formulations of biologics for intravesical instillation
EP3149187B1 (en) 2014-05-30 2020-04-29 Braskem S.A. Modified microorganisms comprising an optimized system for oligosaccharide utilization and methods of using same
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
AU2015292550A1 (en) 2014-07-23 2017-02-16 Robert Schwartz Precision chemical ablation and treatment of tissues
CA2957790A1 (en) 2014-08-13 2016-02-18 Akeso Biomedical, Inc. Antimicrobial compounds and compositions, and uses thereof
US10913736B2 (en) 2014-08-22 2021-02-09 University Of Washington Specific inhibitors of methionyl-tRNA synthetase
WO2016048689A1 (en) 2014-09-23 2016-03-31 Avidas Pharmaceuticals Llc Delivery and induction of therapeutic agents and uses thereof
US10410749B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US10357157B2 (en) 2014-10-21 2019-07-23 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features
US10325685B2 (en) 2014-10-21 2019-06-18 uBiome, Inc. Method and system for characterizing diet-related conditions
US9710606B2 (en) 2014-10-21 2017-07-18 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US10381112B2 (en) 2014-10-21 2019-08-13 uBiome, Inc. Method and system for characterizing allergy-related conditions associated with microorganisms
US10366793B2 (en) 2014-10-21 2019-07-30 uBiome, Inc. Method and system for characterizing microorganism-related conditions
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
BR102014028009B1 (pt) 2014-11-10 2023-04-18 Universidade Federal De Pelotas Composições filmogênicas para bioadesivos anestésicos tópicos (bats) para liberação controlada de princípios ativos e bioadesivos anestésicos tópicos
GB201421013D0 (en) 2014-11-26 2015-01-07 Turzi Antoine New standardizations & medical devices for the preparation of platelet rich plasma (PRP) or bone marrow centrate (BMC)
EP3226849A4 (en) 2014-12-03 2018-05-09 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
CN107427548A (zh) 2014-12-08 2017-12-01 Jjsk 研发私人有限公司 载体分子组合物及相关方法
CA2972233A1 (en) 2014-12-26 2016-06-30 Conjugon, Inc. Methods and compositions for growth, storage, and use of bacterial preparations for wound and surface treatments
US11040022B2 (en) 2015-02-05 2021-06-22 William H. Cross, III Compositions and methods for pain relief
BR112017019349A2 (pt) 2015-03-11 2018-06-05 Melinta Therapeutics Inc compostos antimicrobianos e métodos de fabricação e uso dos mesmos
SG11201707506WA (en) 2015-03-13 2017-10-30 Evolve Biosystems Inc Compositions that metabolize or sequester free sugar monomers and uses thereof
IL294055A (en) 2015-03-20 2022-08-01 Childrens Nat Medical Ct Generating virus or other antigen-specific t cells from a naive t cell population
WO2016164705A1 (en) 2015-04-10 2016-10-13 Omar Abdel-Rahman Ali Immune cell trapping devices and methods for making and using the same
MX2017013562A (es) 2015-04-23 2018-05-28 Kaleido Biosciences Inc Reguladores de microbioma y usos relacionados de los mismos.
WO2016191545A1 (en) 2015-05-26 2016-12-01 Advaxis, Inc. Personalized delivery vector-based immunotherapy and uses thereof
CN108024563A (zh) 2015-08-11 2018-05-11 艾索生物医药公司 提高家畜中重量增加的生物膜抑制组合物
EP3337490A4 (en) 2015-08-20 2019-07-24 Genomatica, Inc. COMPOSITIONS AND MULTIPLEX SYSTEMS FOR COUPLED CELL-FREE TRANSCRIPTION TRANSLATION AND PROTEIN SYNTHESIS AND METHOD FOR USE THEREOF
WO2017051254A1 (en) 2015-09-25 2017-03-30 Legochem Biosciences, Inc. Compositions and methods related to anti-egfr antibody drug conjugates
EP3359085A4 (en) 2015-10-12 2019-09-18 Toth, Landy CONTROLLED AND PRECISE TREATMENT OF HEARTWOVEN
KR102847348B1 (ko) 2015-11-25 2025-08-19 주식회사 리가켐바이오사이언스 펩타이드 그룹을 포함하는 접합체 및 이와 관련된 제조방법
US11173214B2 (en) 2015-11-25 2021-11-16 Legochem Biosciences, Inc. Antibody-drug conjugates comprising branched linkers and methods related thereto
SI3380124T1 (sl) 2015-11-25 2024-10-30 Legochem Biosciences, Inc. Konjugati, ki obsegajo samožrtvujoče skupine in z njimi povezani postopki
CN105363018B (zh) 2015-12-02 2019-08-30 南京碧迪可医药科技有限公司 一种硫肽环素的新用途
WO2017123367A1 (en) 2016-01-11 2017-07-20 Siemens Aktiengesellschaft Program randomization for cyber-attack resilient control in programmable logic controllers
MX2018008906A (es) 2016-01-21 2019-01-10 Selux Diagnostics Inc Metodos para pruebas rapidas de susceptibilidad antimicrobiana.
US20170209553A1 (en) 2016-01-22 2017-07-27 Transderm, Inc. Delivery of botulinum with microneedle arrays
US11268124B2 (en) 2016-01-25 2022-03-08 Bio-Rad Europe Gmbh Digital microbiology
US11771752B2 (en) 2016-03-09 2023-10-03 Prime Bio, Inc. Composition for oral or nasal delivery of tetanus, diphtheria, and pertussis vaccine alone or in combination using neurotoxin associated proteins
WO2017161091A1 (en) 2016-03-16 2017-09-21 Spogen Biotech Inc. Methods for promoting plant health using free enzymes and microorganisms that overexpress enzymes
CA3016922A1 (en) 2016-03-16 2017-09-21 Spogen Biotech Inc. Fusion proteins, recombinant bacteria, and exosporium fragments for animal health and aquaculture
US20170290778A1 (en) 2016-04-12 2017-10-12 Illustris Pharmaceuticals, Inc. Compositions for topical application of compounds
WO2017179775A1 (en) 2016-04-12 2017-10-19 Hugel Inc. Microstructure formulation techniques for botulinum toxin
CN109152803B (zh) 2016-04-25 2022-09-23 普梭梅根公司 用于表征与皮肤相关的病症的方法和系统
KR102399451B1 (ko) 2016-05-27 2022-05-23 입센 바이오팜 리미티드 트립토판 또는 타이로신으로 안정화된 액체 신경독 제형
WO2017210700A1 (en) 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
TWI737742B (zh) 2016-06-22 2021-09-01 德商梅茲製藥有限兩合公司 肉毒桿菌毒素的預填充式注射器系統、具有其之套組以及其之使用
EP3481851B1 (en) 2016-07-08 2021-11-24 Metabolic Explorer Method for the fermentative production of molecules of interest by microorganisms comprising genes coding sugar phosphotransferase system (pts)
WO2018038301A1 (en) 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
KR102552356B1 (ko) 2016-08-26 2023-07-07 에스케이 조인트 벤처스 보툴리눔 독소의 효능 증대를 위한 생분해성 폴리머 제제
WO2018038585A1 (ko) 2016-08-26 2018-03-01 주식회사 에이비바이오 보툴리눔 독소 및 안정화제를 포함하는 액상 제형 및 이의 제조방법
US11554108B2 (en) 2016-08-29 2023-01-17 Xeropedix, Inc. Methods and compositions for treating cutaneous fungal infections
RU2762607C2 (ru) 2016-09-13 2021-12-21 Аллерган, Инк. Стабилизированные небелковые композиции клостридиального токсина
KR102463881B1 (ko) 2016-10-04 2022-11-07 (주)메디톡스 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법
CA3040614A1 (en) 2016-10-26 2018-05-03 Oxy Solutions As Formulations
WO2018083692A1 (en) 2016-11-01 2018-05-11 Tamar Levin Novel methods for modulating protein expression in microorganisms
CN110099682B (zh) 2016-11-14 2023-03-31 杭州多禧生物科技有限公司 偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用
US20180147357A1 (en) 2016-11-29 2018-05-31 Amir Marashi Delivery method for preparation and administration of pharmaceutical compositions
US11040090B2 (en) 2016-12-08 2021-06-22 Prime Bio, Inc Botulinum neurotoxin compositions
WO2018112138A1 (en) 2016-12-15 2018-06-21 Anavi Goffer Sharon Treatment of mental, movement and behavioral disorders
WO2018112419A1 (en) 2016-12-15 2018-06-21 uBiome, Inc. Method and system for characterizing diet-related conditions
US20190343139A1 (en) 2016-12-27 2019-11-14 IMB Inc. Processing human milk for generating compositions of fortified human milk products
CN108322936B (zh) 2017-01-16 2023-06-02 中兴通讯股份有限公司 数据重传的方法及装置
US20190345436A1 (en) 2017-01-17 2019-11-14 White Dog Labs, Inc. Proteinic biomass preparation comprising a non-native organism of the clostridia class
EP3570856A2 (en) 2017-01-18 2019-11-27 Evelo Biosciences, Inc. Methods of treating cancer
KR101744900B1 (ko) 2017-01-20 2017-06-08 주식회사 대웅 보툴리눔 독소를 포함하는 안정한 액상 조성물
KR101776659B1 (ko) 2017-02-27 2017-09-11 주식회사 쿼드메디슨 마이크로 니들 및 이의 제조방법
WO2018175899A1 (en) 2017-03-24 2018-09-27 The Regents Of The University Of Colorado, A Body Corporate Targeted nanogels for urinary bladder therapies
WO2018195097A1 (en) 2017-04-17 2018-10-25 The Regents Of The University Of California Engineered commensal bacteria and methods of use
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
EP3622289B1 (de) 2017-05-11 2023-08-23 Immundiagnostik AG Verfahren und testbesteck zur quantitativen bestimmung von biomarkern in fäkalproben
CN110913868A (zh) 2017-05-24 2020-03-24 Atgc 股份有限公司 用于治疗足痛疾病的包括肉毒杆菌毒素和透明质酸的药物组合物以及使用其治疗足痛疾病的方法
US10912823B2 (en) 2017-05-31 2021-02-09 Allergan, Inc. Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin
FR3067928B1 (fr) 2017-06-23 2020-02-28 Fondation Mediterranee Infection Procede de conservation d'un echantillon de bacteries
EP3644971A4 (en) 2017-06-26 2021-03-31 Bonti, Inc. CLOSTRIDIAL NEUROTOXIN FORMULATIONS AND USE
BR112019028301A2 (pt) 2017-07-05 2020-07-14 Evelo Biosciences, Inc. composições e métodos para tratar câncer com o uso de bifidobacterium animalis ssp. lactis
SG11202001335UA (en) 2017-08-14 2020-03-30 Psomagen Inc Disease-associated microbiome characterization process
US12161703B2 (en) 2017-08-28 2024-12-10 Revance Therapeutics, Inc. Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders
EP3675883A4 (en) 2017-08-30 2021-05-12 Aobiome LLC MICROORGANISMS OXIDIZING AMMONIA FOR THE TREATMENT OF BUTTERFLY ERYTHEMA, ATHLETE'S FOOT, CONTACT DERMATITIS, SWEAT AND BODY ODORS
JP7369690B2 (ja) 2017-09-08 2023-10-26 エヴェロ バイオサイエンシズ，インコーポレーテッド 細菌の細胞外小胞
US10849960B2 (en) 2017-09-08 2020-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer
CA3075270A1 (en) 2017-09-08 2019-03-14 Evelo Biosciences, Inc. Extracellular vesicles from prevotella
KR20200064112A (ko) 2017-10-03 2020-06-05 크리티테크, 인크. 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
WO2019075452A1 (en) 2017-10-13 2019-04-18 Evelo Biosciences, Inc. IDENTIFICATION OF BACTERIA FOR CANCER THERAPY
CA3082696A1 (en) 2017-11-13 2019-05-16 Extremochem, Lda. Neutral glycosylated amides and dianionic glucuronidated acids as stabilizers for biological molecules
JP2021502964A (ja) 2017-11-14 2021-02-04 エヴェロ バイオサイエンシズ，インコーポレーテッド ブラウティア（Ｂｌａｕｔｉａ）株を使用して疾患を処置するための組成物及び方法
EP3713420A4 (en) 2017-11-22 2021-08-25 Aobiome LLC TOPICAL USE AND DELIVERY OF AMMONIA COXIDIZING MICRO-ORGANISMS
EP3716768A4 (en) 2017-11-22 2021-08-25 Aobiome LLC TOPICAL USE AND ADMINISTRATION OF MICROORGANISMS OXIDIZING AMMONIA
CA3083953A1 (en) 2017-12-11 2019-06-20 Board Of Regents, The University Of Texas System Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
CN108205008B (zh) 2017-12-28 2020-04-21 深圳大学 一种基于有机光电化学晶体管的毒素传感器及其制备方法
CA3087778A1 (en) 2018-01-07 2019-07-11 Avraham Amir High-load microneedles and compositions for skin augmentation
AU2019212338B2 (en) 2018-01-24 2024-07-11 Omnigen Research, Llc Bacillus combination for administration to animals
WO2019152667A1 (en) 2018-01-31 2019-08-08 Evelo Biosciences, Inc. Compositions and methods for treating immune disorders using lachnospiraceae bacteria
CN112118849A (zh) 2018-02-06 2020-12-22 瑞珍实验室 交联透明质酸及与prp/bmc的组合
BR112020015639A2 (pt) 2018-02-06 2021-03-30 Evelo Biosciences, Inc. Composições e métodos para o tratamento de câncer e distúrbios imunológicos usando bactérias veillonella
KR102063475B1 (ko) 2018-02-22 2020-01-09 주식회사 에이비바이오 보툴리눔 독소, 안정화제, 및 국소마취제를 포함하는 액상 제형 및 이의 제조방법
US20210076724A1 (en) 2018-02-28 2021-03-18 C-Lecta Gmbh Enzymatic in-situ fortification of food with functional carbohydrates
WO2019178055A1 (en) 2018-03-12 2019-09-19 Evelo Biosciences, Inc. Extracellular vesicles from burkholderia
EP3766529A4 (en) 2018-03-14 2022-03-23 Beacon Medcare (HK) Limited Composition for purification of biofluids
WO2019178487A2 (en) 2018-03-15 2019-09-19 Evelo Biosciences, Inc. Compositions and methods for treating disease using klebsiella quasipneumoniae subsp. similipneumoniae
WO2019178490A1 (en) 2018-03-15 2019-09-19 Evelo Biosciences, Inc. Compositions and methods for treating cancer and inflammation using klebsiella oxytoca
EP3764988A4 (en) 2018-03-15 2022-04-20 Adepthera LLC GEL-FORMING POLYPEPTIDES
WO2019178494A1 (en) 2018-03-15 2019-09-19 Evelo Biosciences, Inc. Compositions and methods for treating cancer and inflammation using tyzzerella nexilis
US20190321427A1 (en) 2018-04-18 2019-10-24 G&S Laboratories, Inc. Compositions to Treat Anal Fissures
EP3787668B1 (en) 2018-05-03 2023-10-25 Crigasseni AG Probiotic bacterial strains producing antimicrobial proteins and compositions comprising these for use in the treatment of clostridium difficile infection
WO2019226599A1 (en) 2018-05-22 2019-11-28 Alkalidx, Inc. Diagnostics and treatments of anesthetic insensitive subjects
US11464858B2 (en) 2018-06-23 2022-10-11 University Of Wyoming Magnetic nanoparticle delivery system for pain therapy
CA3112394A1 (en) 2018-09-13 2020-03-19 Allergan, Inc. Clostridial toxin - hyaluronic acid compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140120077A1 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and Methods for Safe Treatment of Rhinitis

Also Published As

Publication number Publication date
MX2023004911A (es) 2023-05-16
US12409211B2 (en) 2025-09-09
SI3432916T1 (sl) 2020-01-31
AU2017326253A1 (en) 2019-04-11
CA3036095A1 (en) 2018-03-22
CY1122263T1 (el) 2020-11-25
PL3436054T5 (pl) 2023-01-30
KR20230004945A (ko) 2023-01-06
JP7675053B2 (ja) 2025-05-12
RU2019110912A3 (enExample) 2020-11-30
LT3436054T (lt) 2019-11-25
US12171816B2 (en) 2024-12-24
IL265109B2 (en) 2024-05-01
AU2021282546B2 (en) 2025-03-20
PL3436054T3 (pl) 2020-06-15
EP3639848A3 (en) 2020-12-16
DK3436054T4 (da) 2022-08-29
RS59600B2 (sr) 2022-10-31
JP2019526611A (ja) 2019-09-19
SI3436054T1 (sl) 2020-01-31
KR20190053884A (ko) 2019-05-20
US20210369821A1 (en) 2021-12-02
HUE046290T2 (hu) 2020-02-28
JP2022179500A (ja) 2022-12-02
EP3432916A1 (en) 2019-01-30
US20230173041A1 (en) 2023-06-08
AU2025204621A1 (en) 2025-07-10
DK3432916T3 (da) 2019-11-11
AU2017326253B2 (en) 2021-10-21
MX2019002835A (es) 2019-09-04
WO2018053021A1 (en) 2018-03-22
JP7217700B2 (ja) 2023-02-03
AU2017327369A1 (en) 2019-05-02
CN117959415A (zh) 2024-05-03
CN109803673A (zh) 2019-05-24
DK3436054T3 (da) 2019-11-11
PL3432916T3 (pl) 2020-04-30
HUE046449T2 (hu) 2020-03-30
US20190247476A1 (en) 2019-08-15
EP3436054B2 (en) 2022-07-27
CA3035473A1 (en) 2018-03-22
RU2762607C2 (ru) 2021-12-21
US20190351034A1 (en) 2019-11-21
EP3639848A2 (en) 2020-04-22
US10973890B2 (en) 2021-04-13
KR102635959B1 (ko) 2024-02-14
KR20240023684A (ko) 2024-02-22
US20240252604A1 (en) 2024-08-01
CY1122276T1 (el) 2020-11-25
JP2025121944A (ja) 2025-08-20
EP3436054B1 (en) 2019-08-14
US12144847B2 (en) 2024-11-19
KR20190053214A (ko) 2019-05-17
US20180071361A1 (en) 2018-03-15
CO2019003630A2 (es) 2019-06-28
ES2755816T3 (es) 2020-04-23
BR112019004935A2 (pt) 2019-06-04
RU2019110912A (ru) 2020-10-15
WO2018053004A3 (en) 2018-04-26
KR102480965B1 (ko) 2022-12-26
WO2018053004A2 (en) 2018-03-22
CL2019000586A1 (es) 2019-07-26
EP3432916B1 (en) 2019-08-14
ES2755816T5 (es) 2022-10-24
SA519401298B1 (ar) 2021-12-21
AU2021282546A1 (en) 2022-01-06
TW202247855A (zh) 2022-12-16
IL265109B1 (en) 2024-01-01
RU2019110875A (ru) 2020-10-15
SI3436054T2 (sl) 2022-09-30
KR102444230B1 (ko) 2022-09-19
EP3436054A2 (en) 2019-02-06
ES2755815T3 (es) 2020-04-23
HRP20191966T1 (hr) 2020-01-24
US20230355724A1 (en) 2023-11-09
HRP20191966T4 (hr) 2022-09-16
PH12019500501A1 (en) 2019-05-27
TW201822786A (zh) 2018-07-01
KR20220132013A (ko) 2022-09-29
US20230355723A1 (en) 2023-11-09
JP2019526609A (ja) 2019-09-19
US20210290739A1 (en) 2021-09-23
RU2019110875A3 (enExample) 2021-01-12
US20240299509A1 (en) 2024-09-12
IL265109A (enExample) 2019-04-30
IL308091A (en) 2023-12-01
EP3626259A1 (en) 2020-03-25
TWI773686B (zh) 2022-08-11
SMT201900625T1 (it) 2020-01-14
CN109803672A (zh) 2019-05-24
BR112019004929A2 (pt) 2019-06-04
PT3436054T (pt) 2019-11-19
PT3432916T (pt) 2019-11-20
KR20250038828A (ko) 2025-03-19
RS59600B1 (sr) 2020-01-31
US10369190B2 (en) 2019-08-06

Similar Documents

Publication Publication Date Title
KR102558892B1 (ko) 안정화된 비단백질 클로스트리듐 독소 조성물
HK40026309A (en) Stabilized non-protein clostridial toxin compositions
HK40003855B (en) Stabilized non-protein clostridial toxin compositions
HK40003855A (en) Stabilized non-protein clostridial toxin compositions

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220913

Application number text: 1020197010226

Filing date: 20190410

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20221012

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221215

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230426

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230719

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230719

End annual number: 3

Start annual number: 1

PG1601 Publication of registration